Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13225898 | 0.86 | KMT2A (0.62) | KMT2ALMNAMEN1HTTCYP2D6 | |
| SCHEMBL17471132 | 0.83 | NAMPT (0.43) | CYP2C19KMT2ALMNAHTTCYP2D6 | |
| SCHEMBL17471822 | 0.81 | LMNA (0.43) | KMT2ALMNAHTTCYP2D6KCNH2 | |
| SCHEMBL13225931 | 0.81 | KMT2A (0.55) | KMT2ALMNAHTTCYP2D6KCNH2 | |
| SCHEMBL16418435 | 0.81 | CYP2C19 (0.48) | CYP2C19KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL17471129 | 0.80 | HDAC2 (0.42) | KMT2AMEN1HTTCYP2D6KCNH2 | |
| SCHEMBL17471127 | 0.80 | TPSAB1 (0.45) | CYP2D6KCNH2HRH3 | |
| SCHEMBL1564353 | 0.79 | KMT2A (0.55) | CYP2C19KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL1564349 | 0.79 | CYP2C19 (0.56) | CYP2C19KMT2ALMNAMEN1CYP2C9 | |
| SCHEMBL14713195 | 0.79 | CYP2C19 (0.49) | CYP2C19KMT2ALMNAMEN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580415-B2 | Compounds | PROXIMAGEN LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| US-20160024080-A1 | NEW COMPOUNDS | PROXIMAGEN, LLC | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024080-A1 | NEW COMPOUNDS | QSOX1, MAOB, MAOA | CYP2C19 108/4885KMT2A 4162/4885LMNA 1714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.